Oncoinvent ASAOSL: ONCIN

Oncoinvent ASA - Disclosure of large shareholding

· Issued by Oncoinvent ASA

Summary by 6ix AI

On 22 September 2026, Linc AB agreed to lend all 555,362 of its shares in Oncoinvent ASA to the managers of Oncoinvent's private placement and retail offering, so shares allocated in Tranche 1 and the Retail Offering could be settled on delivery against payment. Linc AB keeps a right to get the same number of shares back, and its total position stays at 12.40%.

Key details

  • The managers are ABG Sundal Collier ASA and DNB Carnegie, a part of DNB Bank ASA. The Share Lending Agreement is between Oncoinvent ASA, the managers, Hadean and Linc AB.
  • The placement and retail offering, completed as disclosed on 22 September 2026, was for 1,650,000 new shares at NOK 90.00 per share.
  • Before the loan, Linc AB held 555,362 shares, or 12.40% of shares and votes. After the loan it holds 0 shares and a right to re-delivery of 555,362 shares, equal to 12.40% (physically settled).
  • Linc AB was allocated 192,888 shares in the Private Placement. After delivery it will hold 192,888 shares, or 3.15% of the 6,128,412 shares and votes after registration of the share capital increase. After the lent shares are returned, it will hold 748,250 shares, or 12.21%.

What’s still pending

  • The share loan will be settled by returning an equivalent number of new shares after the share capital increase is registered with the Norwegian Register of Business Enterprises.

6ix AI wrote this summary from the release below and checked it against the release.

Reference is made to the stock exchange announcement by Oncoinvent ASA (the "Company") on 22 September 2026 regarding the successful completion of a private placement and retail offering of 1,650,000 new shares at NOK 90.00 per share, and to the share lending agreement entered into between the Company, ABG Sundal Collier ASA and DNB Carnegie, a part of DNB Bank ASA (the "Managers"), Hadean and Linc AB (the "Share Lending Agreement").

On 22 September 2026, Linc AB agreed to lend 555,362 shares in the Company to the Managers under the Share Lending Agreement, to facilitate delivery-versus-payment settlement of shares allocated in Tranche 1 and the Retail Offering. The share loan will be settled by re-delivery of an equivalent number of new shares following registration of the share capital increase with the Norwegian Register of Business Enterprises.

Before the share lending, Linc AB held 555,362 shares in the Company, corresponding to 12.40% of the shares and votes. Following the share lending, Linc AB holds 0 shares (0.00%) and a right to re-delivery of 555,362 shares, corresponding to 12.40% of the shares and votes (physically settled). The total position (shares and financial instruments) is unchanged at 12.40%.

Linc AB has been allocated 192,888 Offer Shares in the Private Placement. Following delivery of the allocated shares, Linc AB will hold 192,888 shares, corresponding to 3.15% of the Company's 6,128,412 shares and votes following registration of the share capital increase. Following re-delivery of the lent shares, Linc AB will hold 748,250 shares, corresponding to 12.21% of the shares and votes.

This information is subject to the disclosure requirements pursuant to section 4-2 of the Norwegian Securities Trading Act.

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: [email protected]

https://news.cision.com/oncoinvent-asa/r/oncoinvent-asa---disclosure-of-large-shareholding,c4399671

(c) 2026 Cision. All rights reserved., source Press Releases - English

Oncoinvent ASA on 6ix

Earlier from Oncoinvent

All Oncoinvent news releases